No abstract

Centella asiatica has long been known as one of medicinal plants. Profound study is needed to be able to find out the responses of Pegagan to various treatments in order to increase centelloside content. It was also previously reported that the highest asiaticoside content was found at the lowland pegagan, Pantai Labu. Current study on planted lowland pegagan of Deli Serdang with 2.38% of asiaticoside content was aimed to know the response of the plants to phosphorus fertilizing, elicitorand harvesting time related to biomass production from leaves, petioles, roots and tendrils. Phosphorus fertilizer was applied in four levels: 0, 18, 36 and 54 kg P 2 O 5 .ha-1 , which affected centelloside synthesis, and elicitor of methyl jasmonate was given at three levels: 0, 100, 200 μM, while harvesting time was set up at 56, 70 and 84 days after planting (DAP). Data showed that the best combination for biomass production was obtained when there was no elicitor and harvesting was done at 84 DAP. The best combination between methyl jasmonate hormone and harvesting period in both fresh weight of leaves and petioles as well as roots was obtained when there was no hormone and harvesting time was 84 days old.

No abstract

Indonesia has a variety of biological natural resources. One of the plants that thrive is pegagan (Centella asiatica). This study aims to investigate the response of pegagan to phosphorus fertilizer on growth components and phytochemical content. This plant is very useful because of the bioactive content contained in these plants. This research was conducted using a single factor with six levels of P2O5 fertilizer dosage with a non-factorial randomized block design repeated 3 times. The levels of fertilizer dosage are 0, 20, 40, 60, 80, 100 kg P2O5/ha. The application of phosphorus had no significant effects on growth component; length of petiole, total leaf area, number of stolons and biomass production of Centella asiatica in acid soil conditions. The doses of phosphorus given to Centella asiatica plants reaches 40 kg P2O5/ha (F2) in which the fertilized plants tend to offer higher results than those with no fertilizers. Centella asiatica can still grow well even though the land conditions are very acidic. The phytochemical screening of leaves and roots of Centella asiatica was studied and showed positive tests for saponin, tannin, phenolic, flavonoid, triterpenoid, steroid and glycoside and negative for alkaloid.

Background: Cancer patients are considered susceptible to coronavirus disease (COVID-19) due to an immunosuppressive state. This study determined the prevalence of cancer in COVID-19 patients, severe events, case fatality rate, history of anticancer therapy associated with severe events, and type of cancer in cancer patients with COVID-19 in the world. Methods: This study used a meta-analysis study approach, sourcing studies from various countries related to cancer and COVID-19. Inclusion and exclusion criteria were established to select studies. A PRISMA flowchart was presented to assess the selection process. Data from inclusion studies were analyzed using Review Manager 5.4. Results: The prevalence of cancer in COVID-19 patients was 4.63% (95% CI, 3.78-5.49%) worldwide. The lowest prevalence was the Asian study group with 2.36% (95% CI, 1.86-2.87%) and the highest prevalence was the European study group with 10.93% (95% CI, 6.62-15.24%). About 43.26% (95% CI, 34.71-51.80%) of cancer patients with COVID-19 experienced severe events of COVID-19. In total, 58.13% (95% CI, 42.79-73.48%) of cancer patients with COVID-19 who in the last month had a history of anticancer therapy experienced severe events. The prevalence of lung cancer in cancer patients with COVID-19 was 20.23% (95% CI, 7.67-32.78%). Forest plots are also presented related to the results of meta-analysis research. Conclusions: High prevalence of cancer among COVID-19 patients indicates the susceptibility of cancer patients to SARS-CoV-2 infection. Cancer in COVID-19 patients and use of anticancer therapy increase severe events of COVID-19.